- Home
- SLRX vs CDT Comparison
SLRX vs CDT Comparison
Compare SLRX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- CDT
- Stock Information
- Founded
- SLRX N/A
- CDT 2019
- Country
- SLRX United States
- CDT United States
- Employees
- SLRX N/A
- CDT N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- CDT Health Care
- Exchange
- SLRX Nasdaq
- CDT Nasdaq
- Market Cap
- SLRX 3.6M
- CDT 4.2M
- IPO Year
- SLRX N/A
- CDT N/A
- Fundamental
- Price
- SLRX $3.21
- CDT $2.56
- Analyst Decision
- SLRX
- CDT
- Analyst Count
- SLRX 0
- CDT 0
- Target Price
- SLRX N/A
- CDT N/A
- AVG Volume (30 Days)
- SLRX 197.9K
- CDT 526.9K
- Earning Date
- SLRX 11-10-2025
- CDT 11-14-2025
- Dividend Yield
- SLRX N/A
- CDT N/A
- EPS Growth
- SLRX N/A
- CDT N/A
- EPS
- SLRX N/A
- CDT N/A
- Revenue
- SLRX N/A
- CDT N/A
- Revenue This Year
- SLRX N/A
- CDT N/A
- Revenue Next Year
- SLRX N/A
- CDT N/A
- P/E Ratio
- SLRX N/A
- CDT N/A
- Revenue Growth
- SLRX N/A
- CDT N/A
- 52 Week Low
- SLRX $3.16
- CDT $2.38
- 52 Week High
- SLRX $108.00
- CDT $2,198.40
- Technical
- Relative Strength Index (RSI)
- SLRX 37.04
- CDT 52.30
- Support Level
- SLRX $3.55
- CDT $2.78
- Resistance Level
- SLRX $3.97
- CDT $3.22
- Average True Range (ATR)
- SLRX 0.31
- CDT 0.34
- MACD
- SLRX -0.07
- CDT -0.12
- Stochastic Oscillator
- SLRX 3.72
- CDT 8.46
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.